The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...
The U.S. Food and Drug Administration reports a pet food company is voluntarily withdrawing some of their beef and chicken ...
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.
While one brand has withdrawn the affected products, a second, Darwin's Natural Pet Products, has not, according to the FDA.
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
We wouldn’t allow a new drug to be sold without thorough testing for safety and efficacy, so why should AI be any different?
Answers Pet Food and Darwin’s Natural Pet Products, were found to have produced pet food that was contaminated with the ...
A growing body of research shows that exposure can increase the risk of prostate, kidney and testicular cancers. The ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.